Featured Research

from universities, journals, and other organizations

Some Ethnic Groups More Susceptible To Adverse Drug Reactions

Date:
May 6, 2006
Source:
BMJ-British Medical Journal
Summary:
Some ethnic groups may be more susceptible to adverse drug reactions, finds a study published on the British Medical Journal web site.

Some ethnic groups may be more susceptible to adverse drug reactions, finds a study published on the British Medical Journal web site.

Adverse drug reactions (ADRs) are an important cause of ill health and death. Several factors including genetic make up, age, sex, and even diet, can all alter a patient's susceptibility to ADRs. But it is not known to what extent susceptibility to ADRs might depend on ethnic group, whether as a result of genetic or cultural factors.

Researchers searched the scientific literature and identified 24 studies that included data for adverse reactions to cardiovascular drugs for at least two ethnic groups. Differences in study quality were assessed to identify and minimise bias.

They found that the risk of angio-oedema (swelling) with blood pressure lowering drugs was three times greater in black patients than non-black patients. The risk of cough was also nearly three times higher in East Asian patients compared with white patients.

For clot-busting therapy, the risk of bleeding increased 1.5-fold in black compared with non-black patients.

Some ethnic groups may be more susceptible to adverse reactions during treatment with cardiovascular drugs, say the authors. These findings may help doctors present more accurate and relevant data to their patients when prescribing cardiovascular therapy. However, differences in study quality and inconsistent reporting of harms mean that these results need to be interpreted cautiously, they add.

Future studies must report both adverse reactions and racial and ethnic classifications more fully, if we are to discover how they are linked, they conclude.


Story Source:

The above story is based on materials provided by BMJ-British Medical Journal. Note: Materials may be edited for content and length.


Cite This Page:

BMJ-British Medical Journal. "Some Ethnic Groups More Susceptible To Adverse Drug Reactions." ScienceDaily. ScienceDaily, 6 May 2006. <www.sciencedaily.com/releases/2006/05/060506103939.htm>.
BMJ-British Medical Journal. (2006, May 6). Some Ethnic Groups More Susceptible To Adverse Drug Reactions. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2006/05/060506103939.htm
BMJ-British Medical Journal. "Some Ethnic Groups More Susceptible To Adverse Drug Reactions." ScienceDaily. www.sciencedaily.com/releases/2006/05/060506103939.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins